Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System - Seite 3
About Rimidi
Created by doctors, Rimidi’s leading clinical management platform empowers healthcare organizations to optimize clinical workflows, enhance patient experiences and
achieve quality objectives. By bringing together clinical decision support, remote patient monitoring and patient reported outcomes in a unified, composable, FHIR-based platform, Rimidi supports a
broad range of clinical use cases and institutional priorities across large and small healthcare organizations. For more information, visit rimidi.com and follow us on Twitter and LinkedIn.
About Desert Oasis Healthcare
Formed in 1981 as one of the first medical groups in the desert communities of southern California, Desert Oasis Healthcare (DOHC) continues to
advance with changes in the healthcare market. DOHC provides primary and immediate care, home health, palliative care, and other services to more than 60,000 members/patients living in the greater
Coachella Valley and the Morongo Basin of Riverside and San Bernardino counties. The multidisciplinary and comprehensive care programs of DOHC are committed to educating individuals on preventative
health care in their daily lives, reflected in the DOHC motto, "Your Health. Your Life. Our Passion." For more information, visit http://www.mydohc.com.
Lesen Sie auch
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results,
performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as
“should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any
discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to the development and commercial success of our
Digihaler products family; our ability to successfully compete in the marketplace, including our ability to develop and commercialize biopharmaceutical products, competition for our innovative
medicines, including AUSTEDO, AJOVY and COPAXONE, our ability to achieve expected results from investments in our product pipeline, our ability to develop and commercialize additional
pharmaceutical products, and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantial indebtedness; our business and operations in general,
including, the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and costs and delays resulting from the extensive
pharmaceutical regulation to which we are subject; compliance, regulatory and litigation matters, including failure to comply with complex legal and regulatory environments; other financial and
economic risks; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2022, including in the section captioned “Risk Factors.” Forward-looking statements
speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.